Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
Dow Jones Industrial Average
) is trading down 155.0 points (-1%) at 15,254 as of Wednesday, May 29, 2013, 12:35 p.m. ET. During this time, 291.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 594.8 million. The NYSE advances/declines ratio sits at 466 issues advancing vs. 2,548 declining with 68 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Holding back the Dow today is
), which is lagging the broader Dow index with an 83-cent decline (-2.9%) bringing the stock to $28.18. This single loss is lowering the Dow Jones Industrial Average by 6.28 points or roughly accounting for 4.1% of the Dow's overall loss. Volume for Pfizer currently sits at 25 million shares traded vs. an average daily trading volume of 33.9 million shares.
Pfizer has a market cap of $205.99 billion and is part of the health care sector and drugs industry. Shares are up 15.7% year to date as of Tuesday's close. The stock's dividend yield sits at 3.3%.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company has a P/E ratio of 20.5, above the S&P 500 P/E ratio of 17.7.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.
- You can view the full Pfizer Ratings Report.
Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE